FibroBiologics, Inc. SEC filings FBLG

FibroBiologics, Inc. has 242 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form ARS, was filed on May 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, new debt, unregistered share sale). The company's fiscal year ends on December 31.

FibroBiologics, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Oct 19, 2026 —
EFFECT Filing Oct 19, 2026 —
POS AM Filing Oct 13, 2026 —
POS AM Filing Oct 13, 2026 —
D Filing Oct 13, 2026 —
8-K Current report
Material agreement, New debt, Unregistered share sale
Oct 8, 2026 Oct 7, 2026
8-K Current report
Shareholder vote results, Regulation FD disclosure
Sep 18, 2026 Sep 17, 2026
SCHEDULE 13D Ownership over 5% (active) Sep 17, 2026 —
D Filing Sep 16, 2026 —
4 Insider transaction Sep 15, 2026 Sep 15, 2026
8-K Current report
Material agreement, Unregistered share sale
Sep 15, 2026 Sep 15, 2026
DEFA14A Additional proxy material Sep 9, 2026 —
3 Initial insider ownership Sep 1, 2026 Aug 20, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Aug 24, 2026 Aug 20, 2026
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2026 —
10-Q Quarterly report Jul 31, 2026 Jun 30, 2026
DEF 14A Proxy statement Jul 31, 2026 Sep 17, 2026
8-K Current report
Listing notice
Jul 24, 2026 Jul 22, 2026
PRE 14A Preliminary proxy statement Jul 17, 2026 Sep 17, 2026
EFFECT Filing Jul 16, 2026 —
424B3 Prospectus Jul 16, 2026 —
3 Initial insider ownership Jul 16, 2026 Jul 8, 2026
S-3 Shelf registration Jul 10, 2026 —
8-K Current report
Officer or director change, Regulation FD disclosure
Jul 9, 2026 Jul 2, 2026
D Filing Jun 29, 2026 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Jun 29, 2026 Jun 25, 2026
4 Insider transaction Jun 23, 2026 Jun 23, 2026
4 Insider transaction Jun 23, 2026 Jun 23, 2026
4 Insider transaction Jun 23, 2026 Jun 23, 2026
4 Insider transaction Jun 23, 2026 Jun 23, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 23, 2026 Jun 22, 2026
8-K Current report
Material agreement
May 6, 2026 May 5, 2026
424B5 Prospectus supplement May 6, 2026 —
8-K Current report
Officer or director change
May 5, 2026 May 4, 2026
ARS Annual report to shareholders May 5, 2026 Dec 31, 2025
DEFA14A Additional proxy material May 5, 2026 —
DEF 14A Proxy statement May 5, 2026 May 5, 2026
4 Insider transaction May 4, 2026 May 4, 2026
4 Insider transaction May 4, 2026 May 4, 2026
4 Insider transaction May 4, 2026 May 4, 2026
4 Insider transaction May 4, 2026 May 4, 2026
424B5 Prospectus supplement May 1, 2026 —
8-K Current report
Material agreement
May 1, 2026 May 1, 2026
10-Q Quarterly report Apr 30, 2026 Mar 31, 2026
PRE 14A Preliminary proxy statement Apr 22, 2026 Apr 22, 2026
8-K Current report
Regulation FD disclosure, Other events
Apr 20, 2026 Mar 9, 2026
8-K Current report
Bylaw or fiscal year change
Apr 17, 2026 Apr 16, 2026
8-K/A Amended current report
Material agreement, Agreement ended, Other events
Apr 9, 2026 Apr 3, 2026
SCHEDULE 13G Ownership over 5% (passive) Apr 9, 2026 —
8-K Current report
Material agreement, Other events
Apr 9, 2026 Apr 3, 2026
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Apr 3, 2026 Mar 30, 2026
8-K Current report
Material agreement, Regulation FD disclosure
Apr 2, 2026 Mar 31, 2026
424B4 Prospectus Apr 1, 2026 —
EFFECT Filing Mar 31, 2026 —
CORRESP Letter to the SEC Mar 27, 2026 —
CORRESP Letter to the SEC Mar 27, 2026 —
S-1 Registration statement Mar 27, 2026 —
UPLOAD Letter from the SEC Mar 24, 2026 —
DRS Filing Mar 20, 2026 —
10-K/A Amended annual report Mar 13, 2026 Dec 31, 2025
8-K Current report
Officer or director change
Mar 6, 2026 Mar 4, 2026
4 Insider transaction Mar 5, 2026 Mar 4, 2026
4 Insider transaction Mar 4, 2026 Mar 2, 2026
4 Insider transaction Mar 3, 2026 Mar 2, 2026
4 Insider transaction Mar 2, 2026 Feb 27, 2026
10-K Annual report Feb 24, 2026 Dec 31, 2025
8-K Current report
Shareholder vote results
Feb 23, 2026 Feb 20, 2026
8-K Current report
Listing notice
Feb 6, 2026 Feb 3, 2026
8-K Current report
Listing notice
Jan 2, 2026 Dec 30, 2025
EFFECT Filing Dec 30, 2025 —
424B3 Prospectus Dec 30, 2025 —
CORRESP Letter to the SEC Dec 29, 2025 —
UPLOAD Letter from the SEC Dec 29, 2025 —
DEFA14A Additional proxy material Dec 29, 2025 —
DEF 14A Proxy statement Dec 29, 2025 Feb 20, 2026
S-1 Registration statement Dec 23, 2025 —
PRE 14A Preliminary proxy statement Dec 18, 2025 Dec 18, 2025
DEF 14A Proxy statement Dec 18, 2025 Dec 18, 2025
D Filing Dec 16, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Dec 15, 2025 Dec 14, 2025
424B5 Prospectus supplement Dec 15, 2025 —
4 Insider transaction Dec 12, 2025 Dec 11, 2025
D Filing Dec 3, 2025 —
D Filing Dec 3, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Nov 25, 2025 Nov 24, 2025
424B5 Prospectus supplement Nov 25, 2025 —
424B5 Prospectus supplement Nov 20, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
Nov 19, 2025 Nov 18, 2025
10-Q Quarterly report Oct 31, 2025 Sep 30, 2025
8-K Current report
Listing notice
Aug 8, 2025 Aug 4, 2025
10-Q Quarterly report Jul 31, 2025 Jun 30, 2025
8-K/A Amended current report
Unregistered share sale
Jul 18, 2025 Dec 20, 2024
8-K Current report
Unregistered share sale
Jul 18, 2025 Jun 20, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 17, 2025 —
8-K Current report
Listing notice
Jul 3, 2025 Jul 1, 2025
8-K Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
Jun 16, 2025 Jun 16, 2025
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Jun 13, 2025 Jun 12, 2025
4 Insider transaction Jun 12, 2025 Jun 12, 2025
4 Insider transaction Jun 12, 2025 Jun 12, 2025
4 Insider transaction Jun 12, 2025 Jun 12, 2025
4 Insider transaction Jun 12, 2025 Jun 12, 2025
4 Insider transaction Jun 12, 2025 Jun 12, 2025
4 Insider transaction Jun 10, 2025 Jun 9, 2025
3 Initial insider ownership Jun 10, 2025 Jun 9, 2025
8-K Current report
Officer or director change, Regulation FD disclosure
Jun 9, 2025 Jun 9, 2025
SCHEDULE 13G Ownership over 5% (passive) Jun 6, 2025 —
4 Insider transaction May 27, 2025 May 27, 2025
10-Q Quarterly report May 14, 2025 Mar 31, 2025
8-K Current report
Officer or director change
May 5, 2025 May 2, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 23, 2025 —
DEF 14A Proxy statement Apr 23, 2025 Dec 31, 2024
PRE 14A Preliminary proxy statement Apr 11, 2025 Dec 31, 2024
10-K Annual report Mar 31, 2025 Dec 31, 2024
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
SCHEDULE 13G Ownership over 5% (passive) Feb 12, 2025 —
EFFECT Filing Feb 10, 2025 —
8-K Current report
Unregistered share sale
Feb 7, 2025 Jan 7, 2025
CORRESP Letter to the SEC Feb 6, 2025 —
UPLOAD Letter from the SEC Feb 6, 2025 —
S-3 Shelf registration Feb 3, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jan 30, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jan 29, 2025 —
8-K Current report
Officer or director change
Jan 24, 2025 Jan 23, 2025
EFFECT Filing Jan 21, 2025 —
POS AM Filing Jan 17, 2025 —
EFFECT Filing Jan 14, 2025 —
424B4 Prospectus Jan 14, 2025 —
S-1/A Amended registration statement Jan 10, 2025 —
CORRESP Letter to the SEC Jan 10, 2025 —
UPLOAD Letter from the SEC Jan 6, 2025 —
8-K Current report
Material agreement, New debt, Unregistered share sale, Officer or director change, Regulation FD disclosure
Dec 31, 2024 Dec 27, 2024
4 Insider transaction Dec 30, 2024 Dec 27, 2024
4 Insider transaction Dec 30, 2024 Dec 27, 2024
4 Insider transaction Dec 30, 2024 Dec 27, 2024
S-1 Registration statement Dec 30, 2024 —
8-K Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
Dec 23, 2024 Dec 20, 2024
8-K Current report
Material agreement, Agreement ended, Unregistered share sale
Dec 20, 2024 Dec 19, 2024
4 Insider transaction Dec 9, 2024 Dec 9, 2024
4 Insider transaction Dec 5, 2024 Dec 3, 2024
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
8-K Current report
Officer or director change, Other events
Oct 29, 2024 Oct 25, 2024
8-K Current report
Material agreement
Sep 24, 2024 Sep 19, 2024
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Aug 28, 2024 Aug 27, 2024
4 Insider transaction Aug 27, 2024 Aug 27, 2024
4 Insider transaction Aug 27, 2024 Aug 27, 2024
4 Insider transaction Aug 27, 2024 Aug 27, 2024
4 Insider transaction Aug 27, 2024 Aug 27, 2024
4 Insider transaction Aug 27, 2024 Aug 27, 2024
8-K Current report
Unregistered share sale, Regulation FD disclosure
Aug 27, 2024 Aug 26, 2024
EFFECT Filing Aug 14, 2024 —
POS AM Filing Aug 13, 2024 —
3/A Filing Aug 13, 2024 Jan 24, 2024
3/A Filing Aug 13, 2024 Jan 24, 2024
3/A Filing Aug 13, 2024 Jan 24, 2024
3/A Filing Aug 13, 2024 Jan 24, 2024
3/A Filing Aug 13, 2024 Jan 24, 2024
3/A Filing Aug 13, 2024 Jan 24, 2024
4 Insider transaction Aug 12, 2024 Aug 12, 2024
4 Insider transaction Aug 12, 2024 Aug 12, 2024
3/A Filing Aug 12, 2024 Jan 24, 2024
3/A Filing Aug 12, 2024 Jan 24, 2024
10-Q Quarterly report Aug 7, 2024 Jun 30, 2024
ARS Annual report to shareholders Jul 8, 2024 Dec 31, 2023
DEFA14A Additional proxy material Jul 8, 2024 —
DEF 14A Proxy statement Jul 8, 2024 Jul 8, 2024
PRE 14A Preliminary proxy statement Jun 27, 2024 Jun 27, 2024
8-K Current report
Bylaw or fiscal year change
Jun 27, 2024 Jun 25, 2024
424B4 Prospectus Jun 26, 2024 —
EFFECT Filing Jun 25, 2024 —
CORRESP Letter to the SEC Jun 21, 2024 —
CORRESP Letter to the SEC Jun 21, 2024 —
CORRESP Letter to the SEC Jun 18, 2024 —
S-1 Registration statement Jun 18, 2024 —
UPLOAD Letter from the SEC Jun 17, 2024 —
DRS Filing Jun 10, 2024 —
RW Filing Jun 6, 2024 —
S-1/A Amended registration statement Jun 4, 2024 —
S-1/A Amended registration statement May 15, 2024 —
S-8 Employee stock plan registration May 15, 2024 —
10-Q Quarterly report May 14, 2024 Mar 31, 2024
8-K Current report
Other events
Apr 26, 2024 Apr 26, 2024
S-1 Registration statement Apr 26, 2024 —
DRS Filing Apr 12, 2024 —
EFFECT Filing Mar 28, 2024 —
424B4 Prospectus Mar 28, 2024 —
CORRESP Letter to the SEC Mar 27, 2024 —
S-1/A Amended registration statement Mar 26, 2024 —
CORRESP Letter to the SEC Mar 26, 2024 —
UPLOAD Letter from the SEC Mar 25, 2024 —
S-1/A Amended registration statement Mar 15, 2024 —
CORRESP Letter to the SEC Mar 15, 2024 —
4 Insider transaction Mar 8, 2024 Mar 1, 2024
3 Initial insider ownership Mar 6, 2024 Mar 1, 2024
10-K Annual report Feb 29, 2024 Dec 31, 2023
UPLOAD Letter from the SEC Feb 26, 2024 —
8-K Current report
Other events
Feb 20, 2024 Feb 20, 2024
3 Initial insider ownership Feb 15, 2024 Jan 24, 2024

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
FBLG (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Houston, TX
SEC filer status
, Emerging growth company
SEC CIK
1958777
Former names
FibroBiologics Inc. (until Feb 6, 2024)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.